An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer.

Trial Profile

An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2014

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms DAPROCA-1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2014 Planned End Date changed from 1 Nov 2012 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top